Nathanael S Gray

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/169605/publications.pdf

Version: 2024-02-01

395 papers	50,309 citations	1793 106 h-index	2289 206 g-index
437 all docs	437 docs citations	437 times ranked	64785 citing authors

#	Article	IF	Citations
1	INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors. Cancer Discovery, 2022, 12, 356-371.	7.7	68
2	Targeting transcription cycles in cancer. Nature Reviews Cancer, 2022, 22, 5-24.	12.8	59
3	Novel Macrocyclic Peptidomimetics Targeting the Polo-Box Domain of Polo-Like Kinase 1. Journal of Medicinal Chemistry, 2022, 65, 1915-1932.	2.9	5
4	A Novel HER2-Selective Kinase Inhibitor Is Effective in HER2 Mutant and Amplified Nonâ€“Small Cell Lung Cancer. Cancer Research, 2022, 82, 1633-1645.	0.4	18
5	Discovery and Optimization of Tau Targeted Protein Degraders Enabled by Patient Induced Pluripotent Stem Cells-Derived Neuronal Models of Tauopathy. Frontiers in Cellular Neuroscience, 2022, 16, 801179.	1.8	14
6	Inhibiting ERK5 Overcomes Breast Cancer Resistance to Anti-HER2 Therapy By Targeting the G1â€“S Cell-Cycle Transition. Cancer Research Communications, 2022, 2, 131-145.	0.7	3
7	A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas. Blood Advances, 2022, 6, 3332-3338.	2.5	4
8	Selective Macrocyclic Inhibitors of DYRK1A/B. ACS Medicinal Chemistry Letters, 2022, 13, 577-585.	1.3	3
9	Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC. Bioorganic and Medicinal Chemistry Letters, 2022, 68, 128718.	1.0	7
10	Development of PDE6D and CK1Î± Degraders through Chemical Derivatization of FPFT-2216. Journal of Medicinal Chemistry, 2022, 65, 747-756.	2.9	15
11	A preclinical platform for assessing antitumor effects and systemic toxicities of cancer drug targets. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2110557119.	3.3	5
12	Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts. Cancer Discovery, 2022, 12, 1760-1781.	7.7	15
13	An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer. Nature Cancer, 2022, 3, 402-417.	5.7	65
14	Publication Criteria and Requirements for Studies on Protein Kinase Inhibitorsâ”€What Is Expected?. Journal of Medicinal Chemistry, 2022, 65, 6973-6974.	2.9	10
15	Synthesis and Structureâ€“Activity relationships of cyclin-dependent kinase 11 inhibitors based on a diaminothiazole scaffold. European Journal of Medicinal Chemistry, 2022, 238, 114433.	2.6	3
16	Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors. Nature Communications, 2022, 13, 2530.	5.8	29
17	The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug. Journal of Medicinal Chemistry, 2022, 65, 7581-7594.	2.9	11
18	Abstract LB076: Unleashing cell-intrinsic inflammation as a strategy to kill AML blasts. Cancer Research, 2022, 82, LB076-LB076.	0.4	0

#	Article	IF	Citations
19	Cereblon covalent modulation through structure-based design of histidine targeting chemical probes. RSC Chemical Biology, 2022, 3, 1105-1110.	2.0	23
20	Temporal resolution of gene derepression and proteome changes upon PROTAC-mediated degradation of BCL11A protein in erythroid cells. Cell Chemical Biology, 2022, 29, 1273-1287.e8.	2.5	14
21	Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations. Molecular Oncology, 2021, 15, 27-42.	2.1	15
22	Discovery of a Pyrimidothiazolodiazepinone as a Potent and Selective Focal Adhesion Kinase (FAK) Inhibitor. ACS Medicinal Chemistry Letters, 2021, 12, 30-38.	1.3	9
23	Fragment-based covalent ligand discovery. RSC Chemical Biology, 2021, 2, 354-367.	2.0	65
24	Selective degradation-inducing probes for studying cereblon (CRBN) biology. RSC Medicinal Chemistry, 2021, 12, 1381-1390.	1.7	17
25	The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability Identification. International Journal of Molecular Sciences, 2021, 22, 566.	1.8	62
26	Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins. Cell Reports, 2021, 34, 108532.	2.9	54
27	Targeted brachyury degradation disrupts a highly specific autoregulatory program controlling chordoma cell identity. Cell Reports Medicine, 2021, 2, 100188.	3.3	15
28	An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence. Cancer Cell, 2021, 39, 240-256.e11.	7.7	143
29	Targeting oncoproteins with a positive selection assay for protein degraders. Science Advances, 2021, 7, .	4.7	26
30	Discovery and resistance mechanism of a selective CDK12 degrader. Nature Chemical Biology, 2021, 17, 675-683.	3.9	69
31	Generation of a chemical genetic model for JAK3. Scientific Reports, 2021, 11, 10093.	1.6	5
32	Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo. Nature Chemical Biology, 2021, 17, 954-963.	3.9	73
33	ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer. Nature Cancer, 2021, 2, 503-514.	5.7	72
34	Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation. Cancer Discovery, 2021, 11, 2564-2581.	7.7	58
35	Cancer stem cell marker DCLK1 reprograms small extracellular vesicles toward migratory phenotype in gastric cancer cells. Proteomics, 2021, 21, e2000098.	1.3	15
36	Acute pharmacological degradation of Helios destabilizes regulatory T cells. Nature Chemical Biology, 2021, 17, 711-717.	3.9	52

#	Article	IF	Citations
37	Discovery of a Potent Degrader for Fibroblast Growth Factor Receptor 1/2. Angewandte Chemie - International Edition, 2021, 60, 15905-15911.	7.2	25
38	The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. Blood, 2021, 138, 1966-1979.	0.6	16
39	Discovery of a Potent Degrader for Fibroblast Growth Factor Receptor 1/2. Angewandte Chemie, 2021, 133, 16041-16047.	1.6	5
40	Dual targeting of salt inducible kinases and CSF1R uncouples bone formation and bone resorption. ELife, 2021, 10, .	2.8	12
41	The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer. Cell, 2021, 184, 3143-3162.e32.	13.5	103
42	Exploring Ligand-Directed N-Acyl-N-alkylsulfonamide-Based Acylation Chemistry for Potential Targeted Degrader Development. ACS Medicinal Chemistry Letters, 2021, 12, 1302-1307.	1.3	5
43	The Cyclin-Dependent Kinase 8 (CDK8) Inhibitor DCA Promotes a Tolerogenic Chemical Immunophenotype in CD4⁺ T Cells via a Novel CDK8-GATA3-FOXP3 Pathway. Molecular and Cellular Biology, 2021, 41, e0008521.	1.1	3
44	TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma. Cancer Cell, 2021, 39, 1262-1278.e7.	7.7	49
45	Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. Cell, 2021, 184, 4753-4771.e27.	13.5	99
46	Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma. European Journal of Medicinal Chemistry, 2021, 221, 113481.	2.6	27
47	Synthesis and structure-activity relationships of targeted protein degraders for the understudied kinase NEK9. Current Research in Chemical Biology, 2021, 1, 100008.	1.4	3
48	Mammalian cell proliferation requires noncatalytic functions of O-GlcNAc transferase. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	48
49	PRM-LIVE with Trapped Ion Mobility Spectrometry and Its Application in Selectivity Profiling of Kinase Inhibitors. Analytical Chemistry, 2021, 93, 13791-13799.	3.2	20
50	Development of Highly Potent and Selective Pyrazolopyridine Inhibitor of CDK8/19. ACS Medicinal Chemistry Letters, 2021, 12, 1689-1693.	1.3	7
51	MALT1 Degradation with a Proteolysis-Targeting Chimera for the Treatment of Activated B-Cell Type Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 269-269.	0.6	2
52	Abemaciclib is a potent inhibitor of DYRK1A and HIP kinases involved in transcriptional regulation. Nature Communications, 2021, 12, 6607.	5.8	15
53	Prospects for Antibacterial Discovery and Development. Journal of the American Chemical Society, 2021, 143, 21127-21142.	6.6	51
54	Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in Neuroblastoma. Frontiers in Oncology, 2021, 11, 773186.	1.3	11

#	Article	IF	Citations
55	Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia, 2020, 34, 625-629.	3.3	9
56	Structureâ€“Activity Relationship Study of Covalent Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors. ACS Medicinal Chemistry Letters, 2020, 11, 346-352.	1.3	14
57	Development and Characterization of a Wee1 Kinase Degrader. Cell Chemical Biology, 2020, 27, 57-65.e9.	2.5	68
58	Benzopyrimidodiazepinone inhibitors of TNK2. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126948.	1.0	7
59	A broad-spectrum antiviral molecule, QL47, selectively inhibits eukaryotic translation. Journal of Biological Chemistry, 2020, 295, 1694-1703.	1.6	3
60	CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer. Cancer Cell, 2020, 37, 37-54.e9.	7.7	138
61	Exploring Targeted Degradation Strategy for Oncogenic KRASG12C. Cell Chemical Biology, 2020, 27, 19-31.e6.	2.5	182
62	Discovery of an AKT Degrader with Prolonged Inhibition of Downstream Signaling. Cell Chemical Biology, 2020, 27, 66-73.e7.	2.5	84
63	Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15. Nature Chemical Biology, 2020, 16, 7-14.	3.9	136
64	Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells. Cell Systems, 2020, 10, 66-81.e11.	2.9	26
65	Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma. ACS Medicinal Chemistry Letters, 2020, 11, 2238-2243.	1.3	11
66	Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development. Cell, 2020, 183, 1714-1731.e10.	13.5	163
67	Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing. Cell Chemical Biology, 2020, 27, 1229-1240.e4.	2.5	19
68	Repurposing of Kinase Inhibitors for Treatment of COVID-19. Pharmaceutical Research, 2020, 37, 167.	1.7	102
69	Catalytic Domain Plasticity of MKK7 Reveals Structural Mechanisms of Allosteric Activation and Diverse Targeting Opportunities. Cell Chemical Biology, 2020, 27, 1285-1295.e4.	2.5	19
70	Discovery of a series of benzopyrimidodiazepinone TNK2 inhibitors via scaffold morphing. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127456.	1.0	4
71	Selective Degradation of GSPT1 by Cereblon Modulators Identified via a Focused Combinatorial Library. ACS Chemical Biology, 2020, 15, 2722-2730.	1.6	46
72	Discovery of Covalent MKK4/7 Dual Inhibitor. Cell Chemical Biology, 2020, 27, 1553-1560.e8.	2.5	10

#	Article	IF	Citations
73	Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules. Nature Communications, 2020, 11, 4687.	5.8	129
74	CDK13 cooperates with CDK12 to control global RNA polymerase II processivity. Science Advances, 2020, 6, .	4.7	79
75	Development of CDK2 and CDK5 Dual Degrader TMXâ€2172. Angewandte Chemie, 2020, 132, 13969-13974.	1.6	2
76	Selective Mediator dependence of cell-type-specifying transcription. Nature Genetics, 2020, 52, 719-727.	9.4	84
77	Identification of a potent and selective covalent Pin1 inhibitor. Nature Chemical Biology, 2020, 16, 979-987.	3.9	40
78	Structure and Characterization of a Covalent Inhibitor of Src Kinase. Frontiers in Molecular Biosciences, 2020, 7, 81.	1.6	17
79	Development of CDK2 and CDK5 Dual Degrader TMXâ€2172. Angewandte Chemie - International Edition, 2020, 59, 13865-13870.	7.2	47
80	Synthesis and Structureâ€“Activity Relationships of DCLK1 Kinase Inhibitors Based on a 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-one Scaffold. Journal of Medicinal Chemistry, 2020, 63, 7817-7826.	2.9	16
81	Discovery of MFH290: A Potent and Highly Selective Covalent Inhibitor for Cyclin-Dependent Kinase 12/13. Journal of Medicinal Chemistry, 2020, 63, 6708-6726.	2.9	23
82	Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition. Science Advances, 2020, 6, eabb2210.	4.7	46
83	Partitioning of cancer therapeutics in nuclear condensates. Science, 2020, 368, 1386-1392.	6.0	281
84	Extracellular-Regulated Protein Kinase 5-Mediated Control of p21 Expression Promotes Macrophage Proliferation Associated with Tumor Growth and Metastasis. Cancer Research, 2020, 80, 3319-3330.	0.4	23
85	Mutantâ€Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drugâ€Resistant Mutations. Angewandte Chemie - International Edition, 2020, 59, 14481-14489.	7.2	75
86	Mutantâ€Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drugâ€Resistant Mutations. Angewandte Chemie, 2020, 132, 14589-14597.	1.6	13
87	Paradoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitors. Nature Communications, 2020, 11, 1383.	5.8	30
88	Discovery of a selective inhibitor of doublecortin like kinase 1. Nature Chemical Biology, 2020, 16, 635-643.	3.9	84
89	Current therapies under investigation for COVID-19: potential COVID-19 treatments. Canadian Journal of Physiology and Pharmacology, 2020, 98, 483-489.	0.7	6
90	A Quantitative Tissue-Specific Landscape of Protein Redox Regulation during Aging. Cell, 2020, 180, 968-983.e24.	13.5	220

#	Article	IF	Citations
91	Light-induced control of protein destruction by opto-PROTAC. Science Advances, 2020, 6, eaay5154.	4.7	139
92	Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent Inhibitors. Cell Chemical Biology, 2020, 27, 525-537.e6.	2.5	36
93	Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. Cancer Cell, 2020, 37, 104-122.e12.	7.7	267
94	Effects of the multiâ€kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia. Journal of Cellular and Molecular Medicine, 2020, 24, 2968-2980.	1.6	16
95	The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations. Journal of Cellular and Molecular Medicine, 2020, 24, 2145-2156.	1.6	2
96	Structure-Based Design of a Potent and Selective Covalent Inhibitor for SRC Kinase That Targets a P-Loop Cysteine. Journal of Medicinal Chemistry, 2020, 63, 1624-1641.	2.9	27
97	SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas. Blood Cancer Journal, 2020, 10, 12.	2.8	34
98	Inhibition of the deubiquitinase USP10 induces degradation of SYK. British Journal of Cancer, 2020, 122, 1175-1184.	2.9	19
99	Tubulin Resists Degradation by Cereblon-Recruiting PROTACs. Cells, 2020, 9, 1083.	1.8	19
100	Defining and Targeting Adaptations to Oncogenic KRASG12C Inhibition Using Quantitative Temporal Proteomics. Cell Reports, 2020, 30, 4584-4599.e4.	2.9	53
101	Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface. ACS Medicinal Chemistry Letters, 2020, 11, 1269-1273.	1.3	22
102	Discovery and Structureâ€“Activity Relationship Study of (Z)-5-Methylenethiazolidin-4-one Derivatives as Potent and Selective Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 4880-4895.	2.9	17
103	Salt-inducible kinase inhibition suppresses acute myeloid leukemia progression in vivo. Blood, 2020, 135, 56-70.	0.6	49
104	Salt-inducible kinase 1 maintains HDAC7 stability to promote pathologic cardiac remodeling. Journal of Clinical Investigation, 2020, 130, 2966-2977.	3.9	29
105	Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma. Journal of Clinical Investigation, 2020, 130, 5875-5892.	3.9	40
106	STRIPAK directs PP2A activity toward MAP4K4 to promote oncogenic transformation of human cells. ELife, 2020, 9, .	2.8	46
107	BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells. Nature, 2019, 572, 676-680.	13.7	89
108	Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations. Nature Communications, 2019, 10, 3468.	5.8	124

#	Article	IF	Citations
109	Pharmacological enhancement of KCC2 gene expression exerts therapeutic effects on human Rett syndrome neurons and Mecp2 mutant mice. Science Translational Medicine, 2019, 11, .	5.8	111
110	Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLUâ€285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. British Journal of Haematology, 2019, 187, 488-501.	1.2	30
111	Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors. ACS Medicinal Chemistry Letters, 2019, 10, 1549-1553.	1.3	47
112	A kinase-independent role for CDK8 in BCR-ABL1+ leukemia. Nature Communications, 2019, 10, 4741.	5.8	33
113	Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation. Cell Chemical Biology, 2019, 26, 1486-1500.	2.5	110
114	Dual Inhibition of TAF1 and BET Bromodomains from the BI-2536 Kinase Inhibitor Scaffold. ACS Medicinal Chemistry Letters, 2019, 10, 1443-1449.	1.3	11
115	Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers. Cell Reports, 2019, 29, 118-134.e8.	2.9	63
116	Small-molecule targeting of brachyury transcription factor addiction in chordoma. Nature Medicine, 2019, 25, 292-300.	15.2	120
117	Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptorâ€“associated kinase 4 (IRAK4). Journal of Biological Chemistry, 2019, 294, 4511-4519.	1.6	14
118	Synthesis and structure activity relationships of a series of 4-amino-1H-pyrazoles as covalent inhibitors of CDK14. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1985-1993.	1.0	5
119	JNK2 Is Required for the Tumorigenic Properties of Melanoma Cells. ACS Chemical Biology, 2019, 14, 1426-1435.	1.6	12
120	Quinoline and thiazolopyridine allosteric inhibitors of MALT1. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1694-1698.	1.0	14
121	Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. Cancer Discovery, 2019, 9, 926-943.	7.7	220
122	BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models. Cancer Cell, 2019, 35, 752-766.e9.	7.7	56
123	CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation. Nature Communications, 2019, 10, 1757.	5.8	159
124	Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype. Cell Chemical Biology, 2019, 26, 792-803.e10.	2.5	103
125	A multitargeted probe-based strategy to identify signaling vulnerabilities in cancers. Journal of Biological Chemistry, 2019, 294, 8664-8673.	1.6	11
126	Cheminformatics Tools for Analyzing and Designing Optimized Small-Molecule Collections and Libraries. Cell Chemical Biology, 2019, 26, 765-777.e3.	2.5	59

#	Article	IF	Citations
127	Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome. Cell Chemical Biology, 2019, 26, 818-829.e9.	2.5	43
128	Peptide-based covalent inhibitors of MALT1 paracaspase. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1336-1339.	1.0	15
129	Discovery of Covalent CDK14 Inhibitors with Pan-TAIRE Family Specificity. Cell Chemical Biology, 2019, 26, 804-817.e12.	2.5	19
130	Development of Dual and Selective Degraders of Cyclinâ€Ðependent Kinases 4 and 6. Angewandte Chemie - International Edition, 2019, 58, 6321-6326.	7.2	179
131	Development of Dual and Selective Degraders of Cyclinâ€Ðependent Kinases 4 and 6. Angewandte Chemie, 2019, 131, 6387-6392.	1.6	11
132	Identification of small molecule inhibitors targeting the Zika virus envelope protein. Antiviral Research, 2019, 164, 147-153.	1.9	14
133	Coordinating Tissue Regeneration Through Transforming Growth Factor-Î² Activated Kinase 1 Inactivation and Reactivation. Stem Cells, 2019, 37, 766-778.	1.4	10
134	Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML. Cell Chemical Biology, 2019, 26, 300-306.e9.	2.5	188
135	Small Molecules Targeting the Flavivirus E Protein with Broad-Spectrum Activity and Antiviral Efficacy in Vivo. ACS Infectious Diseases, 2019, 5, 460-472.	1.8	29
136	Bruton tyrosine kinase degradation as a therapeutic strategy for cancer. Blood, 2019, 133, 952-961.	0.6	117
137	A Chemoproteomic Strategy for Direct and Proteome-Wide Covalent Inhibitor Target-Site Identification. Journal of the American Chemical Society, 2019, 141, 191-203.	6.6	65
138	Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models. ELife, 2019, 8, .	2.8	184
139	Targeting T-ALL Cells with Potent Activators of the PP2A Protein Phosphatase Tumor Suppressor. Blood, 2019, 134, 406-406.	0.6	0
140	Targeting Salt-Inducible Kinase 3 As a Therapeutic Approach for Acute Myeloid Leukemia. Blood, 2019, 134, 3941-3941.	0.6	0
141	SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform. Cell Chemical Biology, 2018, 25, 460-470.e6.	2.5	95
142	Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2801-E2810.	3.3	67
143	ERK5 is activated by oncogenic BRAF and promotes melanoma growth. Oncogene, 2018, 37, 2601-2614.	2.6	50
144	BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism. Blood, 2018, 131, 2047-2059.	0.6	61

#	Article	IF	Citations
145	Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands. Nature Chemical Biology, 2018, 14, 405-412.	3.9	176
146	RASâ€“MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFRâ€“MEK Blockade. Molecular Cancer Therapeutics, 2018, 17, 1526-1539.	1.9	39
147	Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). Journal of Medicinal Chemistry, 2018, 61, 4249-4255.	2.9	141
148	It Takes Two To Target: A Study in KRAS Dimerization. Biochemistry, 2018, 57, 2289-2290.	1.2	5
149	Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nature Communications, 2018, 9, 476.	5.8	44
150	Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations. Cancer Cell, 2018, 33, 173-186.e5.	7.7	201
151	EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma. Cancer Cell, 2018, 33, 202-216.e6.	7.7	116
152	The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations. Cell Systems, 2018, 6, 13-24.	2.9	327
153	Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nature Chemical Biology, 2018, 14, 163-170.	3.9	376
154	ER Stress Signaling Promotes the Survival of Cancer â€œPersister Cellsâ€•Tolerant to EGFR Tyrosine Kinase Inhibitors. Cancer Research, 2018, 78, 1044-1057.	0.4	87
155	Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors. Cell Chemical Biology, 2018, 25, 135-142.e5.	2.5	58
156	High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma. Journal of Investigative Dermatology, 2018, 138, 1582-1590.	0.3	46
157	Kinase inhibitors: the road ahead. Nature Reviews Drug Discovery, 2018, 17, 353-377.	21.5	679
158	The dTAG system for immediate and target-specific protein degradation. Nature Chemical Biology, 2018, 14, 431-441.	3.9	629
159	Development of Highly Potent and Selective Steroidal Inhibitors and Degraders of CDK8. ACS Medicinal Chemistry Letters, 2018, 9, 540-545.	1.3	67
160	Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression. Cancer Discovery, 2018, 8, 59-73.	7.7	96
161	CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discovery, 2018, 8, 216-233.	7.7	503
162	A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader. Cell Chemical Biology, 2018, 25, 88-99.e6.	2.5	313

#	Article	IF	Citations
163	Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13. ELife, 2018, 7, .	2.8	109
164	Targeting the Extracellular Signal-Regulated Kinase 5 Pathway to Suppress Human Chronic Myeloid Leukemia Stem Cells. Stem Cell Reports, 2018, 11, 929-943.	2.3	19
165	A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing. Cancer Immunology Research, 2018, 6, 1511-1523.	1.6	59
166	A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation. Nature Cell Biology, 2018, 20, 1410-1420.	4.6	265
167	First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia. Journal of Medicinal Chemistry, 2018, 61, 8353-8373.	2.9	17
168	Selective Inhibition of the Myeloid Src-Family Kinase Fgr Potently Suppresses AML Cell Growth in Vitro and in Vivo. ACS Chemical Biology, 2018, 13, 1551-1559.	1.6	34
169	Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor. Angewandte Chemie - International Edition, 2018, 57, 11629-11633.	7.2	20
170	Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor. Angewandte Chemie, 2018, 130, 11803-11807.	1.6	4
171	When Kinases Meet PROTACs. Chinese Journal of Chemistry, 2018, 36, 971-977.	2.6	27
172	BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer. Cancer Research, 2018, 78, 5203-5215.	0.4	16
173	Structure of the Human cGASâ€“DNA Complex Reveals Enhanced Control of Immune Surveillance. Cell, 2018, 174, 300-311.e11.	13.5	244
174	How small-molecule inhibitors of dengue-virus infection interfere with viral membrane fusion. ELife, 2018, 7, .	2.8	16
175	Discovery of Immunologically Inspired Small Molecules That Target the Viral Envelope Protein. ACS Infectious Diseases, 2018, 4, 1395-1406.	1.8	27
176	Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains. ACS Chemical Biology, 2018, 13, 2438-2448.	1.6	44
177	Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 7560-7572.	2.9	26
178	Plasticity in binding confers selectivity in ligand-induced protein degradation. Nature Chemical Biology, 2018, 14, 706-714.	3.9	391
179	Inhibition of Flaviviruses by Targeting a Conserved Pocket on the Viral Envelope Protein. Cell Chemical Biology, 2018, 25, 1006-1016.e8.	2.5	68
180	A Novel HCK Inhibitor Kin-8193 Blocks BTK Activity in BTKCys481 Mutated Ibrutinib Resistant B-Cell Lymphomas Driven By Mutated MYD88. Blood, 2018, 132, 40-40.	0.6	9

#	Article	IF	Citations
181	Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. ELife, 2018, 7, .	2.8	125
182	Triple Degradation of BTK, IKZF1 and IKZF3 in B-Cell Malignancies. Blood, 2018, 132, 263-263.	0.6	0
183	Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer. Clinical Cancer Research, 2017, 23, 204-213.	3.2	73
184	THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. Nature Communications, 2017, 8, 14290.	5.8	74
185	Structureâ€"Activity Relationship Study of QL47: A Broad-Spectrum Antiviral Agent. ACS Medicinal Chemistry Letters, 2017, 8, 344-349.	1.3	16
186	A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. Neuro-Oncology, 2017, 19, now261.	0.6	55
187	Discoidin domain receptor 2 mediates collagen-induced activation of membrane-type 1 matrix metalloproteinase in human fibroblasts. Journal of Biological Chemistry, 2017, 292, 6633-6643.	1.6	31
188	Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma. Science Translational Medicine, 2017, 9, .	5.8	53
189	Discovery of a potent dual ALK and EGFR T790M inhibitor. European Journal of Medicinal Chemistry, 2017, 136, 497-510.	2.6	31
190	Covalent Guanosine Mimetic Inhibitors of G12C KRAS. ACS Medicinal Chemistry Letters, 2017, 8, 61-66.	1.3	59
191	Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitors. European Journal of Medicinal Chemistry, 2017, 137, 545-557.	2.6	16
192	A UV-Independent Topical Small-Molecule Approach for Melanin Production in Human Skin. Cell Reports, 2017, 19, 2177-2184.	2.9	59
193	Small-Molecule Inhibitors of LRRK2. Advances in Neurobiology, 2017, 14, 241-264.	1.3	29
194	Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model. Scientific Reports, 2017, 7, 466.	1.6	19
195	Discovery of host-targeted covalent inhibitors of dengue virus. Antiviral Research, 2017, 139, 171-179.	1.9	15
196	Structure-guided development of covalent TAK1 inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 838-846.	1.4	28
197	Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 1320-1328.	1.4	17
198	Identification of compounds with anti-human cytomegalovirus activity that inhibit production of IE2 proteins. Antiviral Research, 2017, 138, 61-67.	1.9	10

#	Article	IF	Citations
199	A benzo[b]thiophene-based selective type 4 S1P receptor agonist. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1-5.	1.0	17
200	Inhibition of USP10 induces degradation of oncogenic FLT3. Nature Chemical Biology, 2017, 13, 1207-1215.	3.9	89
201	Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia. Blood, 2017, 130, 2326-2338.	0.6	66
202	Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors. Cell Reports, 2017, 21, 467-481.	2.9	65
203	Characterization of a highly selective inhibitor of the Aurora kinases. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4405-4408.	1.0	10
204	Vomocytosis of live pathogens from macrophages is regulated by the atypical MAP kinase ERK5. Science Advances, 2017, 3, e1700898.	4.7	45
205	Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma. Cancer Research, 2017, 77, 5068-5076.	0.4	24
206	A Simple Method to Identify Kinases That Regulate Embryonic Stem Cell Pluripotency by High-throughput Inhibitor Screening. Journal of Visualized Experiments, 2017, , .	0.2	2
207	Small-molecule studies identify CDK8 as a regulator of IL-10 in myeloid cells. Nature Chemical Biology, 2017, 13, 1102-1108.	3.9	46
208	Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C. Cell Chemical Biology, 2017, 24, 1005-1016.e3.	2.5	109
209	KRAS G12C Drug Development: Discrimination between Switch II Pocket Configurations Using Hydrogen/Deuterium-Exchange Mass Spectrometry. Structure, 2017, 25, 1442-1448.e3.	1.6	27
210	YY1 Is a Structural Regulator of Enhancer-Promoter Loops. Cell, 2017, 171, 1573-1588.e28.	13.5	749
211	A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell, 2017, 171, 1437-1452.e17.	13.5	2,281
212	BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment. Molecular Cell, 2017, 67, 5-18.e19.	4.5	347
213	Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia. British Journal of Haematology, 2017, 177, 808-813.	1.2	13
214	Synergistic interactions with PI3K inhibition that induce apoptosis. ELife, 2017, 6, .	2.8	25
215	MELK is not necessary for the proliferation of basal-like breast cancer cells. ELife, 2017, 6, .	2.8	86
216	Progress towards a public chemogenomic set for protein kinases and a call for contributions. PLoS ONE, 2017, 12, e0181585.	1.1	131

#	Article	IF	Citations
217	Crystal structure of human IRAK1. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 13507-13512.	3.3	59
218	Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth. PLoS ONE, 2017, 12, e0181178.	1.1	15
219	Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer. Molecular Cancer Therapeutics, 2016, 15, 2096-2106.	1.9	61
220	A Landscape of Pharmacogenomic Interactions in Cancer. Cell, 2016, 166, 740-754.	13.5	1,518
221	Leveraging Gas-Phase Fragmentation Pathways for Improved Identification and Selective Detection of Targets Modified by Covalent Probes. Analytical Chemistry, 2016, 88, 12248-12254.	3.2	31
222	GNF-2 Inhibits Dengue Virus by Targeting Abl Kinases and the Viral E Protein. Cell Chemical Biology, 2016, 23, 443-452.	2.5	57
223	Discovery of a Highly Selective STK16 Kinase Inhibitor. ACS Chemical Biology, 2016, 11, 1537-1543.	1.6	15
224	Sustained Akt Activity Is Required to Maintain Cell Viability in Seborrheic Keratosis, a Benign Epithelial Tumor. Journal of Investigative Dermatology, 2016, 136, 696-705.	0.3	22
225	A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate. Nature Chemical Biology, 2016, 12, 452-458.	3.9	389
226	Discovery of a Series of 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-ones as Selective PI3K-Î˝/Î³ Inhibitors. ACS Medicinal Chemistry Letters, 2016, 7, 908-912.	1.3	15
227	Erk5 Is a Key Regulator of Naive-Primed Transition and Embryonic Stem Cell Identity. Cell Reports, 2016, 16, 1820-1828.	2.9	35
228	Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. Cancer Cell, 2016, 30, 273-289.	7.7	143
229	Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nature Chemical Biology, 2016, 12, 876-884.	3.9	249
230	Mitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survival. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9810-9815.	3.3	66
231	HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood, 2016, 127, 3237-3252.	0.6	93
232	Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma. Blood, 2016, 128, 239-248.	0.6	17
233	Pharmacological targeting of kinases MST1 and MST2 augments tissue repair and regeneration. Science Translational Medicine, 2016, 8, 352ra108.	5.8	271
234	SIKs control osteocyte responses to parathyroid hormone. Nature Communications, 2016, 7, 13176.	5.8	124

#	Article	IF	Citations
235	Activation of HIPK2 Promotes ER Stress-Mediated Neurodegeneration in Amyotrophic Lateral Sclerosis. Neuron, 2016, 91, 41-55.	3.8	75
236	Torin2 Suppresses Ionizing Radiation-Induced DNA Damage Repair. Radiation Research, 2016, 185, 527-538.	0.7	11
237	Development of Chemical Probes for Investigation of Salt-Inducible Kinase Function in Vivo. ACS Chemical Biology, 2016, 11, 2105-2111.	1.6	57
238	NVPâ€TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting Pâ€glycoprotein (PGP1) function. British Journal of Pharmacology, 2016, 173, 613-626.	2.7	26
239	EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. Cancer Research, 2016, 76, 305-318.	0.4	98
240	Inhibiting fungal multidrug resistance by disrupting an activatorâ€“Mediator interaction. Nature, 2016, 530, 485-489.	13.7	120
241	Progress on Covalent Inhibition of KRASG12C. Cancer Discovery, 2016, 6, 233-234.	7.7	21
242	Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor. ACS Medicinal Chemistry Letters, 2016, 7, 476-481.	1.3	17
243	Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis. Cancer Research, 2016, 76, 127-138.	0.4	31
244	Inhibition of IKKÎ± by BAY61-3606 Reveals IKKÎ±-Dependent Histone H3 Phosphorylation in Human Cytomegalovirus Infected Cells. PLoS ONE, 2016, 11, e0150339.	1.1	11
245	Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation. Oncotarget, 2016, 7, 69760-69769.	0.8	41
246	Aberrant Phosphorylation of MEF2C Is Dispensable for Hematopoiesis, and Induces Chemotherapy Resistance and Susceptibility to MARK Kinase Inhibition Therapy in Acute Myeloid Leukemia. Blood, 2016, 128, 436-436.	0.6	0
247	Inhibition of USP10 Induces Degradation of Oncogenic FLT3: A Novel Approach to Therapy of Leukemia. Blood, 2016, 128, 524-524.	0.6	0
248	SnapShot: Kinase Inhibitors I. Molecular Cell, 2015, 58, 708-708.e1.	4.5	14
249	SnapShot: Kinase Inhibitors II. Molecular Cell, 2015, 58, 710-710.e1.	4.5	10
250	EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors. Clinical Cancer Research, 2015, 21, 3913-3923.	3.2	318
251	Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer. Cancer Discovery, 2015, 5, 960-971.	7.7	211
252	Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. Journal of Medicinal Chemistry, 2015, 58, 9296-9308.	2.9	34

#	Article	IF	Citations
253	Suppression of interferon Î² gene transcription by inhibitors of bromodomain and extra-terminal (BET) family members. Biochemical Journal, 2015, 468, 363-372.	1.7	15
254	Tivantinib (ARQ 197) efficacy is independent of MET inhibition in nonâ€smallâ€cell lung cancer cell lines. Molecular Oncology, 2015, 9, 260-269.	2.1	51
255	EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma. Cancer Discovery, 2015, 5, 274-287.	7.7	107
256	The promise and peril of chemical probes. Nature Chemical Biology, 2015, 11, 536-541.	3.9	698
257	Development of small molecules targeting the pseudokinase Her3. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3382-3389.	1.0	53
258	Discovery of a Pyrrolopyrimidine (JH-II-127), a Highly Potent, Selective, and Brain Penetrant LRRK2 Inhibitor. ACS Medicinal Chemistry Letters, 2015, 6, 584-589.	1.3	46
259	Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach. Blood, 2015, 125, 3133-3143.	0.6	23
260	YAP Drives Growth by Controlling Transcriptional Pause Release from Dynamic Enhancers. Molecular Cell, 2015, 60, 328-337.	4.5	228
261	CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer. Cell, 2015, 163, 174-186.	13.5	346
262	Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer. ACS Chemical Biology, 2015, 10, 2687-2696.	1.6	43
263	The ins and outs of selective kinase inhibitor development. Nature Chemical Biology, 2015, 11, 818-821.	3.9	220
264	Development of Selective Covalent Janus Kinase 3 Inhibitors. Journal of Medicinal Chemistry, 2015, 58, 6589-6606.	2.9	94
265	Systematic analysis of <scp>BRAF^V</scp>^{600E} melanomas reveals a role for <scp>JNK</scp>/câ€Jun pathway in adaptive resistance to drugâ€induced apoptosis. Molecular Systems Biology, 2015, 11, 797.	3.2	84
266	Extracellular signalâ€“regulated kinase 5 promotes acute cellular and systemic inflammation. Science Signaling, 2015, 8, ra86.	1.6	37
267	DFG-out Mode of Inhibition by an Irreversible Type-1 Inhibitor Capable of Overcoming Gate-Keeper Mutations in FGF Receptors. ACS Chemical Biology, 2015, 10, 299-309.	1.6	44
268	A Discovery Strategy for Selective Inhibitors of câ€Src in Complex with the Focal Adhesion Kinase SH3/SH2â€binding Region. Chemical Biology and Drug Design, 2015, 86, 144-155.	1.5	10
269	The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma. Gut, 2015, 64, 1454-1465.	6.1	58
270	Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. Leukemia, 2015, 29, 27-37.	3.3	51

#	Article	IF	Citations
271	Discovery of Type II Inhibitors of TGFÎ²-Activated Kinase 1 (TAK1) and Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2 (MAP4K2). Journal of Medicinal Chemistry, 2015, 58, 183-196.	2.9	62
272	Targeting IRAK1/IRAK4 Signaling in Waldenstrom's Macroglobulinemia. Blood, 2015, 126, 4004-4004.	0.6	11
273	HCK Is a Highly Relevant Target of Ibrutinib in MYD88 Mutated Waldenstrom's Macroglobulinemia and Diffuse Large B-Cell Lymphoma. Blood, 2015, 126, 705-705.	0.6	3
274	Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase. PLoS ONE, 2015, 10, e0128364.	1.1	18
275	Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells. Oncotarget, 2015, 6, 31313-31322.	0.8	38
276	Targeting Myddosome Self-Assembly in Waldenstrom's Macroglobulinemia. Blood, 2015, 126, 1563-1563.	0.6	0
277	Genomic and Proteomic Analysis of Primary Chemoresistance and Induction Failure in Acute Myeloid Leukemia. Blood, 2015, 126, 88-88.	0.6	0
278	Interleukin-6 Secretion by Astrocytes Is Dynamically Regulated by PI3K-mTOR-Calcium Signaling. PLoS ONE, 2014, 9, e92649.	1.1	31
279	MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells. ELife, 2014, 3, e01763.	2.8	104
280	Protein kinase IKKÎ²-catalyzed phosphorylation of IRF5 at Ser462 induces its dimerization and nuclear translocation in myeloid cells. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17432-17437.	3.3	89
281	Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases. Biochemical Journal, 2014, 457, 215-225.	1.7	67
282	The LKB1-salt-inducible kinase pathway functions as a key gluconeogenic suppressor in the liver. Nature Communications, 2014, 5, 4535.	5.8	131
283	Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E4869-77.	3.3	154
284	Fluorescent Visualization of Src by Using Dasatinibâ€BODIPY. ChemBioChem, 2014, 15, 1317-1324.	1.3	16
285	Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor. Cancer Cell, 2014, 26, 909-922.	7.7	376
286	Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 12468-12473.	3.3	68
287	The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma. Science Signaling, 2014, 7, ra102.	1.6	80
288	Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?. ACS Chemical Biology, 2014, 9, 1230-1241.	1.6	337

#	Article	IF	Citations
289	Therapeutic Targeting of Oncogenic Kâ€Ras by a Covalent Catalytic Site Inhibitor. Angewandte Chemie - International Edition, 2014, 53, 199-204.	7.2	262
290	CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer. Cell, 2014, 159, 1126-1139.	13.5	498
291	Discovery of Allosteric Bcrâ€“Abl Inhibitors from Phenotypic Screen to Clinical Candidate. Methods in Enzymology, 2014, 548, 173-188.	0.4	19
292	Upregulation of IGF1R by Mutant RAS in Leukemia and Potentiation of RAS Signaling Inhibitors by Small-Molecule Inhibition of IGF1R. Clinical Cancer Research, 2014, 20, 5483-5495.	3.2	16
293	Pharmacological targeting of the pseudokinase Her3. Nature Chemical Biology, 2014, 10, 1006-1012.	3.9	161
294	Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature, 2014, 511, 616-620.	13.7	698
295	Systematic Identification of Culture Conditions for Induction and Maintenance of Naive Human Pluripotency. Cell Stem Cell, 2014, 15, 471-487.	5.2	702
296	A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics. Nature Chemical Biology, 2014, 10, 853-860.	3.9	187
297	Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma. ACS Chemical Biology, 2014, 9, 1086-1091.	1.6	66
298	Screening of DUB activity and specificity by MALDI-TOF mass spectrometry. Nature Communications, 2014, 5, 4763.	5.8	269
299	Structural Mechanisms Determining Inhibition of the Collagen Receptor DDR1 by Selective and Multi-Targeted Type II Kinase Inhibitors. Journal of Molecular Biology, 2014, 426, 2457-2470.	2.0	77
300	In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8895-8900.	3.3	193
301	PIM Kinases Are Essential for Chronic Lymphocytic Leukemia Cell Survival (PIM2/3) and CXCR4-Mediated Microenvironmental Interactions (PIM1). Molecular Cancer Therapeutics, 2014, 13, 1231-1245.	1.9	61
302	Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC. Journal of Clinical Investigation, 2014, 124, 2037-2049.	3.9	102
303	Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. Oncotarget, 2014, 5, 8737-8749.	0.8	72
304	Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor. ACS Chemical Biology, 2013, 8, 2145-2150.	1.6	119
305	Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma. Cancer Research, 2013, 73, 5195-5205.	0.4	153
306	Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR. Cancer Research, 2013, 73, 2574-2586.	0.4	170

#	Article	IF	Citations
307	A public-private partnership to unlock the untargeted kinome. Nature Chemical Biology, 2013, 9, 3-6.	3.9	141
308	Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones. European Journal of Medicinal Chemistry, 2013, 70, 758-767.	2.6	45
309	Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway. Cancer Research, 2013, 73, 834-843.	0.4	171
310	Discovery of a Selective Irreversible BMX Inhibitor for Prostate Cancer. ACS Chemical Biology, 2013, 8, 1423-1428.	1.6	40
311	Synthesis, Structureâ€“Activity Relationships, and In Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials. Journal of Medicinal Chemistry, 2013, 56, 5675-5690.	2.9	308
312	X-ray Crystal Structure of ERK5 (MAPK7) in Complex with a Specific Inhibitor. Journal of Medicinal Chemistry, 2013, 56, 4413-4421.	2.9	29
313	Developing Irreversible Inhibitors of the Protein Kinase Cysteinome. Chemistry and Biology, 2013, 20, 146-159.	6.2	563
314	Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells. PLoS ONE, 2013, 8, e56473.	1.1	38
315	A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in WaldenstrÃ¶m macroglobulinemia. Blood, 2013, 122, 1222-1232.	0.6	306
316	PI3K/AKT Pathway Is Activated By MYD88 L265P and Use Of PI3K-Delta Inhibitors Induces Robust Tumor Cell Killing In Waldenstromâ€™s Macroglobulinemia. Blood, 2013, 122, 4255-4255.	0.6	9
317	Using Small Molecules To Identify Critical Signaling Pathways Of Mutant N-RAS In Acute Leukemia Cells. Blood, 2013, 122, 169-169.	0.6	0
318	Germinal Center Kinase Regulates The Proliferation and Survival Of Diffuse Large B-Cell Lymphoma. Blood, 2013, 122, 643-643.	0.6	0
319	Small Molecule Inhibitors of USP1 Target ID1 Degradation in Leukemic Cells and Cause Cytotoxicity. Blood, 2013, 122, 2906-2906.	0.6	1
320	Kinome-wide Selectivity Profiling of ATP-competitive Mammalian Target of Rapamycin (mTOR) Inhibitors and Characterization of Their Binding Kinetics. Journal of Biological Chemistry, 2012, 287, 9742-9752.	1.6	89
321	Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16986-16991.	3.3	210
322	Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 â€“ 2011). Expert Opinion on Therapeutic Patents, 2012, 22, 1415-1426.	2.4	40
323	Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors. Cancer Discovery, 2012, 2, 934-947.	7.7	255
324	Pyrazolopyridines as inhibitors of the kinase LRRK2: a patent evaluation (WO2011141756). Expert Opinion on Therapeutic Patents, 2012, 22, 709-713.	2.4	2

#	Article	IF	Citations
325	Selective Aurora Kinase Inhibitors Identified Using a Taxol-Induced Checkpoint Sensitivity Screen. ACS Chemical Biology, 2012, 7, 185-196.	1.6	20
326	An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRÎ± and kit. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4579-4584.	1.0	12
327	Development of â€˜DFG-outâ€™ inhibitors of gatekeeper mutant kinases. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5297-5302.	1.0	10
328	GSK2578215A; A potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5625-5629.	1.0	138
329	Leveraging kinase inhibitors to develop small molecule tools for imaging kinases by fluorescence microscopy. Molecular BioSystems, 2012, 8, 2523.	2.9	25
330	Development of ATP-Competitive mTOR Inhibitors. Methods in Molecular Biology, 2012, 821, 447-460.	0.4	41
331	Brain Penetrant LRRK2 Inhibitor. ACS Medicinal Chemistry Letters, 2012, 3, 658-662.	1.3	119
332	Discovery of Potent and Selective Covalent Inhibitors of JNK. Chemistry and Biology, 2012, 19, 140-154.	6.2	286
333	Small-Molecule Inhibitors of the c-Fes Protein-Tyrosine Kinase. Chemistry and Biology, 2012, 19, 529-540.	6.2	32
334	Characterization of TAE684 as a potent LRRK2 kinase inhibitor. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1864-1869.	1.0	80
335	TYK2-STAT1 Pathway Positively Regulates BCL2 Gene Expression in T-Cell Acute Lymphoblastic Leukemia. Blood, 2012, 120, 1470-1470.	0.6	1
336	Deciphering the Critical Pathways of Mutant N-RAS in AML Using Small Molecule Inhibitors.. Blood, 2012, 120, 2455-2455.	0.6	0
337	Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathwayâ€“dependent and PI3K pathwayâ€“independent mechanisms. Nature Medicine, 2011, 17, 1116-1120.	15.2	231
338	Discovery of 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a Potent, Selective, and Orally Available Mammalian Target of Rapamycin (mTOR) Inhibitor for Treatment of Cancer. Journal of Medicinal Chemistry, 2011, 54, 1473-1480.	2.9	195
339	Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a Potent and Selective Inhibitor of Big MAP Kinase 1. ACS Medicinal Chemistry Letters, 2011, 2, 195-200.	1.3	59
340	The Evolving War on Cancer. Cell, 2011, 145, 19-24.	13.5	197
341	Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer. Cancer Discovery, 2011, 1, 78-89.	7.7	455
342	Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nature Chemical Biology, 2011, 7, 203-205.	3.9	380

#	Article	IF	Citations
343	Small molecule modulators of antioxidant response pathway. Current Opinion in Chemical Biology, 2011, 15, 162-173.	2.8	182
344	In Situ Kinase Profiling Reveals Functionally Relevant Properties of Native Kinases. Chemistry and Biology, 2011, 18, 699-710.	6.2	292
345	High-Throughput Kinase Profiling: A More Efficient Approach toward the Discovery of New Kinase Inhibitors. Chemistry and Biology, 2011, 18, 868-879.	6.2	105
346	Discovery of selective irreversible inhibitors for EGFR-T790M. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 638-643.	1.0	62
347	Discovery and optimization of potent and selective benzonaphthyridinone analogs as small molecule mTOR inhibitors with improved mouse microsome stability. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 4036-4040.	1.0	10
348	A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors. Cancer Research, 2011, 71, 6051-6060.	0.4	560
349	Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer. PLoS ONE, 2011, 6, e20351.	1.1	338
350	Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRÎ±, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. Blood, 2010, 115, 4206-4216.	0.6	61
351	A Type-II Kinase Inhibitor Capable of Inhibiting the T315I â€œGatekeeperâ€•Mutant of Bcr-Abl. Journal of Medicinal Chemistry, 2010, 53, 5439-5448.	2.9	73
352	Pharmacological Inhibition of BMK1 Suppresses Tumor Growth through Promyelocytic Leukemia Protein. Cancer Cell, 2010, 18, 258-267.	7.7	181
353	A Structure-Guided Approach to Creating Covalent FGFR Inhibitors. Chemistry and Biology, 2010, 17, 285-295.	6.2	127
354	A Small-Molecule Inducer of the Antioxidant Response Element. Chemistry and Biology, 2010, 17, 537-547.	6.2	73
355	Broad spectrum alkynyl inhibitors of T315I Bcr-Abl. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4196-4200.	1.0	20
356	Discovery of novel 1H-imidazol-2-yl-pyrimidine-4,6-diamines as potential antimalarials. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4027-4031.	1.0	25
357	Targeting Bcrâ€“Abl by combining allosteric with ATP-binding-site inhibitors. Nature, 2010, 463, 501-506.	13.7	525
358	Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function. Nature Chemical Biology, 2010, 6, 359-368.	3.9	201
359	Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors. Molecular Cancer Therapeutics, 2010, 9, 2468-2477.	1.9	15
360	Discovery of 1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a Highly Potent, Selective Mammalian Target of Rapamycin (mTOR) Inhibitor for the Treatment of Cancer. Journal of Medicinal Chemistry, 2010, 53, 7146-7155.	2.9	208

#	Article	IF	Citations
361	Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature, 2009, 462, 1070-1074.	13.7	886
362	Targeting cancer with small molecule kinase inhibitors. Nature Reviews Cancer, 2009, 9, 28-39.	12.8	2,278
363	Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4467-4470.	1.0	77
364	Cell-based optimization of novel benzamides as potential antimalarial leads. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6970-6974.	1.0	15
365	FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resistance Updates, 2009, 12, 81-89.	6.5	95
366	DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival. Cell, 2009, 137, 873-886.	13.5	1,055
367	An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1. Journal of Biological Chemistry, 2009, 284, 8023-8032.	1.6	1,545
368	mTOR mediated anti-cancer drug discovery. Drug Discovery Today: Therapeutic Strategies, 2009, 6, 47-55.	0.5	146
369	N-Myristoylated c-Abl Tyrosine Kinase Localizes to the Endoplasmic Reticulum upon Binding to an Allosteric Inhibitor. Journal of Biological Chemistry, 2009, 284, 29005-29014.	1.6	52
370	Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5916-5919.	1.0	36
371	Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature, 2008, 455, 975-978.	13.7	775
372	Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nature Structural and Molecular Biology, 2008, 15, 1109-1118.	3.6	366
373	Gene expression signatures and small-molecule compounds link a protein kinase to Plasmodium falciparum motility. Nature Chemical Biology, 2008, 4, 347-356.	3.9	203
374	High-throughput kinase profiling as a platform for drug discovery. Nature Reviews Drug Discovery, 2008, 7, 391-397.	21.5	198
375	In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 9059-9064.	3.3	400
376	EML4-ALKFusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer. Clinical Cancer Research, 2008, 14, 4275-4283.	3.2	916
377	Identification of Human Kinases Involved in Hepatitis C Virus Replication by Small Interference RNA Library Screening. Journal of Biological Chemistry, 2008, 283, 29-36.	1.6	95
378	Activity of Plk Inhibitor BI2536 on Myeloma Cells. Blood, 2008, 112, 2764-2764.	0.6	0

#	Article	IF	Citations
379	Inhibition of BCR/ABL-T315I by Dismantling the Hydrophobic Spine.. Blood, 2008, 112, 2129-2129.	0.6	9
380	Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19936-19941.	3.3	334
381	Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 270-275.	3.3	348
382	Verification of a Designed Intramolecular Hydrogen Bond in a Drug Scaffold by Nuclear Magnetic Resonance Spectroscopy. Journal of Medicinal Chemistry, 2007, 50, 5875-5877.	2.9	38
383	Dissection of Bcr-abl Structural Domains Relating to Kinase Auto-Inhibition Using a Forward Mutational Screen with the Non-ATP Competitive Inhibitor GNF-2.. Blood, 2007, 110, 1021-1021.	0.6	1
384	A Unified Mechanism of Tyrosine Kinase Regulation by the Gatekeeper Residue.. Blood, 2007, 110, 223-223.	0.6	1
385	Drug discovery through industry-academic partnerships. , 2006, 2, 649-653.		23
386	Rational design of inhibitors that bind to inactive kinase conformations. Nature Chemical Biology, 2006, 2, 358-364.	3.9	985
387	Design and synthesis of 7H-pyrrolo[2,3-d]pyrimidines as focal adhesion kinase inhibitors. Part 2. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 2689-2692.	1.0	54
388	A General Strategy for Creating â€œInactive-Conformationâ€•Abl Inhibitors. Chemistry and Biology, 2006, 13, 779-786.	6.2	138
389	A Monoselective Sphingosine-1-Phosphate Receptor-1 Agonist Prevents Allograft Rejection in a Stringent Rat Heart Transplantation Model. Chemistry and Biology, 2006, 13, 1227-1234.	6.2	123
390	An efficient rapid system for profiling the cellular activities of molecular libraries. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 3153-3158.	3.3	173
391	Synthesis and Target Identification of Hymenialdisine Analogs. Chemistry and Biology, 2004, 11, 247-259.	6.2	128
392	Sphingosine 1-Phosphate (S1P) Receptor Subtypes S1P1 and S1P3, Respectively, Regulate Lymphocyte Recirculation and Heart Rate. Journal of Biological Chemistry, 2004, 279, 13839-13848.	1.6	559
393	A Combinatorial Scaffold Approach toward Kinase-Directed Heterocycle Libraries. Journal of the American Chemical Society, 2002, 124, 1594-1596.	6.6	181
394	A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature, 2000, 407, 395-401.	13.7	1,001
395	Cheminformatics Tools for Analyzing and Designing Optimized Small Molecule Collections and Libraries. SSRN Electronic Journal, 0, , .	0.4	0